WO2026038162 - PHARMACEUTICAL COMPOSITIONS OF ENT1 INHIBITORS
National phase entry is expected:
Publication Number
WO/2026/038162
Publication Date
19.02.2026
International Application No.
PCT/IB2025/058239
International Filing Date
13.08.2025
Title **
[English]
PHARMACEUTICAL COMPOSITIONS OF ENT1 INHIBITORS
[French]
COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS D'ENT1
Applicants **
ITEOS BELGIUM SA
Inventors
MITTAL, Pankaj
Priority Data
63/683,418
15.08.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4339 | |
| EPO | Filing, Examination, Granting | 50580 | |
| Japan | Filing, Examination, Granting | 3758 | |
| South Korea | Filing, Examination, Granting | 5324 | |
| USA | Filing, Examination, Granting | 14590 |
Total:
78,591
Contact Us
Abstract[English]
Disclosed herein are pharmaceutical compositions comprising an ENT1 inhibitor a pharmaceutically acceptable excipient. In some embodiments, the ENT1 inhibitor is selected from Compound 1 or a hydrate or solvate thereof or pharmaceutically acceptable salts thereof. In some embodiments, the pharmaceutically acceptable excipient is a diluent. Compound 1[French]
L'invention concerne des compositions pharmaceutiques comprenant un inhibiteur d'ENT1, un excipient pharmaceutiquement acceptable. Dans certains modes de réalisation, l'inhibiteur d'ENT1 est choisi parmi le composé 1 ou un hydrate ou un solvate de celui-ci ou des sels pharmaceutiquement acceptables de celui-ci. Dans certains modes de réalisation, l'excipient pharmaceutiquement acceptable est un diluant. Composé 1